

This is a repository copy of *Detecting and discussing sexual problems during chemotherapy for breast cancer*.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/93571/

Version: Accepted Version

Article:

Taylor, S, Harley, C orcid.org/0000-0002-8800-4238, Takeuchi, E et al. (2 more authors) (2013) Detecting and discussing sexual problems during chemotherapy for breast cancer. Breast Journal, 19 (5). pp. 566-567. ISSN 1075-122X

https://doi.org/10.1111/tbj.12168

© 2013 Wiley Periodicals, Inc. This is the peer reviewed version of the following article: Taylor, S., Harley, C., Takeuchi, E., Brown, J. and Velikova, G. (2013), Detecting and Discussing Sexual Problems during Chemotherapy for Breast Cancer. The Breast Journal, 19: 566–567, which has been published in final form at http://dx.doi.org/10.1111/tbj.12168. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



LETTER TO THE EDITOR

Detecting and discussing sexual problems during chemotherapy for breast cancer

To the Editor:

The breast is a unique symbol of femininity playing an important role in body image, selfesteem, as well as sexual pleasure and stimulation (1). Treatment of breast cancer through surgery, chemotherapy, radiotherapy, hormone therapy, or a combination may cause immediate or delayed side-effects that impair sexual function (e.g., dyspareunia, vaginal dryness, or reduced libido) (2, 3). If left unaddressed, sexual function problems may significantly impair patients' quality-of-life (QOL).

Physicians are not only responsible for treating and caring for patients, they are also gatekeepers to support services. For good reason, patient-physician interactions tend to focus on disease symptoms and side-effects during treatment periods, and consequently may omit to discuss certain aspects of qualityof-life including sexual function (4). Research suggests that discussion of sexual function may be disproportionately hindered by communication barriers (5).

In this study we examined the prevalence of dissatisfaction with sexual function during chemotherapy for breast cancer through patient self-report (Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire (6)). We then examined whether those reporting sexual dissatisfaction discussed this issue with their physician during outpatient consultations. Subsequently, we interviewed 10 patients and 10 health professionals about their opinions of routine assessment and discussion of sexual function to identify ways in which current practice could be enhanced.

Fifty-two patients completed the FACT-G questionnaire (mean age 53.4; S.D 10.15, 44% curative, 56% palliative). Twenty-six (50%) completed the satisfaction with sex-life item and of these 8 (15% of the total sample) reported dissatisfaction with sexual function. Older patients were more likely to omit completing the sex-life item.

Four consecutive outpatient consultations were audio-recorded for each of the 52 study patients. Physicians did not receive patients' FACT-G scores. Despite 15% of patients reporting dissatisfaction with sexual function, sexual problems were not discussed in any of the 208 consultations. Menopause and fertility issues were discussed in one consultation (33 year old patient). Relationships and partner support were discussed in 12 consultations.

Thematic analysis of interviews with patients identified that assessment of sexual function using PROMs was acceptable. One patient indicated that they found the questions a little embarrassing but they were not offended by being asked to answer them. Another patient said they were happy to answer sexual function questions as sexuality was an important aspect of their overall wellbeing. Two patients (one early stage, one metastatic disease) did not feel that sexual function was particularly relevant to their treatment. Both women however could see that the questions may be relevant to some breast cancer patients. Some of the interviewees said they would probably speak to a nurse if they had concerns about sexual function whereas other women felt they would deal with the issue themselves or with their partner. Women often felt that at the time of chemotherapy treatment sexual issues were not a particular priority but may be in the future if the problem persists.

Thematic analysis of interviews with 10 healthcare professionals (2 medical oncology consultants, 3 clinical oncology consultants, 2 registrars and 3 specialist nurses) identified several barriers to discussion of sexual issues. Physicians often regarded patients' age as a barrier. They felt older women may not want to talk about sexual issues particularly with a physician who was younger than them. Male also said they physicians would feel uncomfortable raising sexual issues with female patients. Specialist nurses did not raise any concerns in relation to age or gender; they did however indicate that stage of treatment could perhaps be a barrier to discussion. Specialist nurses suggested that women may not be concerned about sexual issues at the time of treatment and that it was an issue that would be more likely to be discussed during the healthcare follow-up period. Some

professionals felt ill equipped to discuss sexual problems with patients, and cited a lack expertise and unclear referral pathways as barriers to discussion. Healthcare professionals acknowledged that sexual functioning was under-discussed in clinical practice but tended to expect patients to initiate discussion of this topic without prompting. Healthcare professionals agreed that screening using PROMs may facilitate and target discussion with patients experiencing difficulties.

In the current study 15% of patients undergoing chemotherapy for breast cancer reported sexual satisfaction problems. These problems were not discussed during oncology consultations. Patients and professionals acknowledged that satisfaction with sexual function was important to some patients during treatment, but identified several barriers to discussion. Using PROMs to screen for sexual problems may facilitate communication identifying by patients who are experiencing sexual difficulty and by providing healthcare professionals with a route to seeking permission to discuss the topic (7, 8). Improvements in communication skills training as well as improved referral pathways to effective sexual health services (9, 10) were identified as key areas for enhancing current practice.

Sally Taylor¹ Clare Harley, PhD^{1, 2} Elena Takeuchi, MD¹ Julia Brown, Prof³* Galina Velikova, Prof¹* ¹Psychosocial Oncology and Clinical Practice Research Group, St James's Institute of Oncology, University of Leeds, UK ²School of Healthcare, University of Leeds, UK ³Clinical Trials and Research Unit, University of Leeds, UK * Joint senior authors

References

1. Emilee G, Ussher JM, Perz J. Sexuality after breast cancer: a review. Maturitas. [Research Support, Non-U.S. Gov't Review]. 2010 Aug;66(4):397-407.

2. Goldfarb SB, Dickler M, Sit L, Fruscione M, Barz T, Atkinson T, et al. Sexual dysfunction in women with breast cancer: Prevalence and severity. Journal of Clinical Oncology. [Conference Abstract]. 2009;1):9558.

3. Berglund G, Nystedt M, Bolund C, Sjoden PO, Rutquist LE. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol. 2001 Jun 1;19(11):2788-96.

4. Takeuchi EE, Keding A, Awad N, Hofmann U, Campbell LJ, Selby PJ, et al. Impact of patient-reported outcomes in oncology: a longitudinal analysis of patient-physician communication. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. [Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 2011 Jul 20;29(21):2910-7.

5. Park ER, Norris RL, Bober SL. Sexual health communication during cancer care: barriers and recommendations. Cancer J. 2009 Jan-Feb;15(1):74-7.

6. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993 Mar;11(3):570-9.

7. Anon JS. The PLISSIT Model: a proposed conceptual scheme for the behavioural treatment of sexual problems. Journal of Sex Education & Therapy. 1976;2:1-15.

8. Halyard MY. The use of real-time patient-reported outcomes and quality-of-life data in oncology clinical practice. Expert Rev Pharmacoecon Outcomes Res. 2011 Oct;11(5):561-70.

9. Horden A. Discussing sexuality in the clinical setting: The impact of a brief training program for oncology health professionals to enhance communication about sexuality. Asia-Pacific Journal of Clinical Oncology. 2009;5:270-7.

10. Taylor S, Harley C, Ziegler L, Brown J, Velikova G. Interventions for sexual problems following treatment for breast cancer: a systematic review. Breast cancer research and treatment. 2011 Sep 9;online first.